Affiliation:
1. University of São Paulo, Brazil
2. Medical School of the ABC, Brazil
Abstract
The objective of this study was to analyze the incidence of chemotherapy-induced nausea and vomiting in women with breast cancer and identify strategies used by them to control these signs and symptoms. Data for this cross-sectional study were collected through interviews during the last cycle of chemotherapy, between August 2011 and March 2012, in a university hospital in the State of São Paulo. The sample consisted of 22 women between the ages of 31 and 70, of whom 77.3% reported nausea and 50% vomiting during treatment. Regarding symptom management, 82% of the women reported having received some information centered on the use of prescribed medication. However, 27.3% did not know what medication they had taken. We concluded that there is a lack of systematic care and institutional protocol to guide professionals in providing standardized information to women so they can better control nausea and vomiting.
Reference20 articles.
1. Phase III trial comparing two dose levels os epirubicin combined with cyclophosphamide, cyclophosphamide, methotrexate, and fluoracil in node-positive breast cancer;Piccart MJ;J Clin Oncol,2001
2. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137;Linden HM;J Clin Oncol,2007
3. Estudo sobre emese aguda e tardia em doentes a efectuar quimioterapia, alta e moderadamente emetizante, em internamento;Santos M;Onco News,2008
4. Análisis de la efectividad de un protocolo de antiemesis implantado en la unidad de oncologia;Huertas-Fernándes MJ;Farm Hosp,2010
5. Antiemetic research: future directions;Olver I;Support Care Cancer,2011
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献